Background--Surrogate endpoint trials test strategies more efficiently but are accompanied by uncertainty about the relationship between changes in surrogate markers and clinical outcomes.
particularly adopted in cardiovascular medicine, where many interventions required years to manifest their effects on clinical outcomes. 4, 5 For example, dyslipidemia is known to be associated with increased risk of cardiovascular events. Investigators have tested the impacts of health interventions on dyslipidemia, hoping that an intervention that targets dyslipidemia in the short term would likewise lead to better cardiovascular outcomes in the long term. However, torcetrapib, a cholesteryl ester transfer protein inhibitor, improved lipid profile dramatically while clinical outcomes were not improved (and there was suggestion of clinical harm). Similarly, there have been several studies where interventions showed benefits on other surrogate endpoints, while the clinical outcomes were unchanged or worsened. [6] [7] [8] Therefore, despite the potential advantages and efficiency, use of surrogate outcomes for testing strategies is accompanied by concern for lack of efficacy on clinical outcomes because of loose (or no) causal relationship between the surrogates and clinically important outcomes, or because of coexisting but unexpected consequences that health interventions may have on pathways other than those of the surrogate outcome. 9, 10 However, the extent of this phenomenon has not been characterized. Our objective was to perform a systematic review of cardiovascular trials published in the highest-impact journals, characterizing the success of these trials in meeting their primary endpoints. We also examined subsequent publication of clinical outcome trials on interventions identified in our review, determining concordance between the surrogate outcome trials and subsequent clinical outcomes trials.
Methods Data Source, Inclusion, and Exclusion Criteria
We searched MEDLINE with PubMed interface to screen all publications in the New England Journal of Medicine (NEJM), Lancet, and JAMA: Journal of the American Medical Association (JAMA) (January 1, 1990 , to December 31, 2011) based on a search for cardiovascular trials using keywords and Medical Subject Heading terms (Table 1) . Studies have shown that trials published in the highest-impact journals have a higher methodological quality, larger sample size, and lower risk of bias. 11 Such journals are more likely to publish important and potentially practice-changing clinical trials.
12,13
We excluded noncardiovascular trials, safety trials, and manuscripts that reported secondary or post hoc analyses. We chose the cutoff date of December 31, 2011, for inclusion of surrogate outcome clinical trials. This decision was made to provide time for publication, in the 3 journals, of pertinent subsequent clinical outcomes trials that followed the included surrogate outcomes clinical trials.
Characterization of Surrogate and Clinical Endpoints and Positive or Negative Results
We first characterized all trials as clinical endpoint trials, or surrogate endpoint trials. Detailed definitions of surrogate endpoints have been provided elsewhere. 1 In brief, study endpoints that could not be perceived and directly related to patients but were derived from tests with plausibly important medical information were considered as surrogate endpoints. outcome trials on those scenarios in any of the aforementioned 6 journals or NEJM, Lancet, or JAMA.
Statistical Analyses
The study was designed by B. 
Results
Between January 1990 and December 2011, the number of articles published in the 3 journals declined, while the number of citations that included "trial*" in the PubMed search remained relatively stable (Table 2 ). In the study period, we manually screened 3016 articles through the systematic search and identified 220 surrogate endpoint trials. There was an increase in the annual number of surrogate endpoint trials from 1990 to 2007 (P<0.01 for trend) and a decline thereafter ( Figure 1 ). From the total of 220 surrogate trials, 157 (71.4%) were positive for their primary outcome. Fifty-nine (26.8%) surrogate endpoint trials were followed by at least 1 clinical endpoint trial. Year of publication had a modest association with presence of subsequent outcome trials (R 2 =0.15), with older trials being slightly more frequently followed by a clinical outcomes trial. Among these 59 surrogate endpoint trials that had a subsequent clinical endpoint trial, in 24 cases the clinical endpoint trial results validated the positive surrogate trials, while in 20 the subsequent clinical endpoint trial was negative (Table 3 ). 14-50 A negative surrogate endpoint trial was less likely to be followed by a positive outcome trial and we identified only 3 such examples (P=0.02, Figure 2 ). Among the 220 surrogate endpoint cardiovascular trials, 56 enrolled primary prevention populations, 138 had a secondary prevention population, and 26 had a hybrid cohort (ie, a mix of primary and secondary prevention patients). There was no difference based on the enrolled population in the proportion of studies that had subsequent clinical outcomes trials (P=0.51, Table 4 ).
From the total of 220 surrogate endpoint cardiovascular trials, 101 had an imaging endpoint, 42 had clinical biomarkers, and 77 had other surrogate endpoints. Trials with an imaging-related primary endpoint were more frequently followed by a clinical outcome trial (37 of 101 versus 22 of 119; P=0.02).
In our robustness search of 6 additional journals (Circulation, Journal of the American College of Cardiology, European Heart Journal, JAMA Internal Medicine, British Medical Journal, and Annals of Internal Medicine) from January 1, 2002, to July 1, 2002, we screened 383 articles and identified 37 eligible surrogate endpoint trials. Most of these trials were small (median sample size: 71 patients) and were positive for their primary surrogate outcome (N=25, 67.5%). Of these 37 trials, the overwhelming majority (N=35, 94.5%) did not have a subsequent clinical outcomes trial. Except for the interval between 1990 and 1991, there was not a major change in the number of clinical trials published in the New England Journal of Medicine, Lancet, and JAMA: Journal of the American Medical Association per year. The number of all publications has had a slight declining trend, whereas the number of publications that had "trial*" anywhere in the article has slightly increased. Data obtained from PubMed search. *P<0.0001 for declining trend.
Discussion
We found that while surrogate endpoint trials published in the highest-impact journals frequently show superiority of the tested intervention, less than one third of them had a clinical outcomes trial of the intervention for the same purpose published in those same highest-impact journals. Moreover, when there was a subsequent clinical outcomes trial, nearly half of them failed to validate the positive impact of the intervention on the surrogate marker. The results were fundamentally robust irrespective of enrolled population or type of the surrogate outcome. The findings were also similarly replicated (if not more pronounced) in a sample cohort from other high-impact journals. Although surrogate markers are intended to ultimately predict benefits for patient-important outcomes, our findings question this premise. The issue may be not that there are flaws in a surrogate endpoint, but that interventions have a multitude of effects beyond the surrogate, and it is difficult to judge the net result on outcomes based on the surrogate endpoint, even one thought to be central to the mechanism of disease or highly predictive of outcomes. The suboptimal rate of outcomes trials that accompany a surrogate endpoint trial is concerning and should draw the attention of investigators and policymakers. The increase in publication of surrogate endpoint cardiovascular trails from 1990 until a few years ago is likely reflective of surging enthusiasm and dominance of surrogate endpoints among investigators and academicians. 2 The decline in recent years, however, possibly reflective of lessons learned from unexpected results of surrogates on clinical endpoints, is encouraging.
Of the surrogate endpoint trials that were accompanied by a clinical outcomes trial, we noticed several positive surrogate endpoint trials that had a related negative clinical outcomes trials. We hypothesize that the disconnect between the surrogate endpoints and clinical outcomes is multifactorial. Some surrogate endpoints might merely be risk markers but not within the causal pathway, and therefore, intervening on them might have had little impact to improve clinical outcomes. 9 Others may have been in the causal pathway but not targeted by the right intervention. Yet, some other surrogate endpoints might have been in the causal pathway but targeted by interventions that had coexisting off-target effects. 6, 51 Trials with positive imaging surrogate endpoints were more frequently followed by clinical outcomes trials. It could be hypothesized that structural changes usually need more time to reflect a change based on an intervention than blood biomarkers and could therefore better predict the ultimate impact of a health intervention. These findings warrant further investigation. The choice regarding our study cohort is worthy of further discussion. We investigated surrogate endpoint cardiovascular trials published in the NEJM, Lancet, and JAMA in order to focus on those most likely to be the highest-impact and highest-quality studies. Although inclusion of all other surrogate endpoint trials for the study could have been ideal, achieving such a task is improbable for our group and many others. A search of merely 6 additional impactful journals, discussed above, retrieved more than 14 000 articles, and expansion to other journals would have made the cohort much larger. Our choice for searching subsequent outcome trials in the top 3 journals should also be discussed. Most often, high-impact cardiovascular clinical endpoint randomized controlled trials are published in these 3 journals and it would be less frequent, if not rare, that an adequately powered well-conducted cardiovascular clinical outcome trial gets published outside of these 3 journals. There could be a potential theoretical concern that the negative clinical outcome trials are less likely to get published in those journals. However, negative clinical outcome trials are commonly published in NEJM, Lancet, and JAMA. 52 The results in a sample cohort of surrogate endpoint cardiovascular trials published in 6 other high-impact journals further support the generalizability of our key findings. In our search of a sample of surrogate endpoint trials in other journals, the few associated clinical endpoint trials, all were identified from the 3 highest-impact journals, with no clinical outcomes trials being found from the other 6 prestigious journals. 32 Multiple negative secondary prevention trials. Despite modest effects on blood pressure, a meta-analysis of available randomized trials did not show a decline in stroke risk, the most profoundly influenced cardiovascular outcome by hypertension 33 Exercise training improved exercise duration and peak oxygen consumption in patients with heart failure O'Connor et al, JAMA 17 Exercise training did not reduce the rate of death or hospitalizations in patients with heart failure Wood et al, N Engl J Med (1991) 34 A low-fat low-cholesterol diet was associated with reduced weight and lower cholesterol levels (including in women) 35 Use of a low-fat diet did not lead to reduced rate of cardiovascular events 36 Losartan compared with captopril was associated with less frequent discontinuation of therapy and a trend towards lower death or hospitalizations in patients with heart failure Pfeffer et al, N Engl J Med (2003) 37 Valsartan was not superior to captopril for reducing all-cause death in patients with heart failure Follath et al, Lancet 38 Compared with dobutamine, levosimendan more frequently led to hemodynamic improvement in patients with heart failure Mebazaa et al, JAMA 39 Compared with dobumtamine, levosimendan did not reduce all-cause mortality Nappo et al, JAMA 40 Use of vitamin C and vitamin E was associated with improved markers of coagulation and oxidation 41 Neither vitamin C nor vitamin D reduced cardiovascular events
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Study Strengths
Our study provides real-world evidence about promises and limitations of surrogate endpoint trials in cardiovascular medicine. Infrequent follow-up with a clinical outcome trial and poor concordance between positive surrogate endpoint trials and subsequent clinical outcome trials are concerning. We also observed that when a surrogate endpoint trial showed negative results, it was rare that a subsequent clinical endpoint trial proved the benefits of the intervention. We believe that our key findings would be helpful not only for investigators and funders but also for clinicians to recognize the benefits and concerns about clinical decisions based on surrogate endpoint trials. For investigators and funders, if the surrogate endpoint trial shows promise for the tested intervention, subsequent investigation with a clinical outcome trial would be the best next step. However, if the surrogate endpoint trial is well conducted and negative, the available finite resources could be shifted towards more promising health interventions. For practitioners and policymakers, including the Food and Drug Administration, it might be best to focus on clinically important endpoints, unless in scenarios where there is no interim way to obtain clinical outcomes from well-conducted randomized trials (eg, young patients with familial hypercholesterolemia or those with rare conditions)-and even then, the label should express the limitations of the evidence. These issues are particularly important as the US Congress debates new legislation that directs the Food and Drug Administration to consider being more permissive in its approval process and to depend more heavily on surrogate endpoints. 53 
Study Limitations
Our study, however, had limitations other than the choice of study cohort discussed above. First, although in many cases the associated clinical outcome trials were negative, a smaller benefit on clinical endpoints could not be excluded. Second, although the surrogate endpoint trials and the identified associated outcome trials were very similar with regards to patient population and interventions, inevitably the subsequent trials may not have been a full replica of the initial surrogate endpoint trials (eg, using the same class of drug, but not necessarily the same agent or the same dose). However, using extremely strict criteria for identicalness of the surrogate endpoint trials and subsequent clinical endpoint trials would mean that an even lower proportion of the 220 surrogate endpoint trials were followed by clinical outcome trials than the 59 that we identified by reasonable clinical similarity. Third, although we believe that our study elucidates some fundamental advantages and challenges of surrogate endpoint trials, the focus was on cardiovascular trials. Therefore, extrapolation to other study fields requires further investigation. Preliminary results from other fields such as oncology concur with our findings. 
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Conclusions
Our findings raise concern about the certainty of assuming efficacy based on surrogate endpoints. Even if used for approval of therapies in urgent situations, postmarketing outcome trials are necessary. The good sensitivity of surrogate endpoint trials for detection of possible benefits, however, is encouraging. Based on our findings, cardiovascular surrogate endpoint trials may be more appropriate for excluding benefit from the patient perspective than for identifying it-and all surrogate endpoint trials should be interpreted in light of the possibility that they might not be validated in a clinical outcomes trial. 
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